Free Trial

Aclaris Therapeutics (ACRS) Competitors

Aclaris Therapeutics logo
$1.45 -0.01 (-0.68%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.50 +0.05 (+3.79%)
As of 09:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACRS vs. STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, and UPB

Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Aclaris Therapeutics vs. Its Competitors

Stoke Therapeutics (NASDAQ:STOK) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Stoke Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

In the previous week, Stoke Therapeutics had 13 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 15 mentions for Stoke Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.51 beat Stoke Therapeutics' score of 0.10 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aclaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Stoke Therapeutics currently has a consensus target price of $23.20, suggesting a potential upside of 93.17%. Aclaris Therapeutics has a consensus target price of $9.71, suggesting a potential upside of 569.95%. Given Aclaris Therapeutics' higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$36.56M17.94-$88.98M$0.7915.20
Aclaris Therapeutics$18.72M8.39-$132.07M-$1.39-1.04

Stoke Therapeutics has a net margin of 26.33% compared to Aclaris Therapeutics' net margin of -732.42%. Stoke Therapeutics' return on equity of 19.08% beat Aclaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics26.33% 19.08% 15.72%
Aclaris Therapeutics -732.42%-30.73%-22.74%

Summary

Stoke Therapeutics beats Aclaris Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACRS vs. The Competition

MetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$158.09M$2.68B$5.50B$8.94B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio-1.048.9826.9720.11
Price / Sales8.39714.59426.02119.76
Price / CashN/A159.8036.8257.86
Price / Book1.014.517.985.56
Net Income-$132.07M$31.26M$3.16B$248.40M
7 Day PerformanceN/A3.57%2.36%4.67%
1 Month Performance-2.68%1.28%2.15%6.64%
1 Year Performance15.08%1.08%33.78%21.31%

Aclaris Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACRS
Aclaris Therapeutics
2.4069 of 5 stars
$1.45
-0.7%
$9.71
+570.0%
+14.2%$158.09M$18.72M-1.04100
STOK
Stoke Therapeutics
3.9931 of 5 stars
$11.35
-2.4%
$23.20
+104.4%
-7.2%$634.96M$36.56M14.37100
SANA
Sana Biotechnology
2.5683 of 5 stars
$2.73
-2.8%
$8.60
+215.0%
-23.4%$633.59MN/A-3.10380Gap Up
MRVI
Maravai LifeSciences
3.727 of 5 stars
$2.41
-2.4%
$6.64
+175.5%
-62.4%$629.01M$259.18M-2.11610
URGN
Urogen Pharma
4.5452 of 5 stars
$13.70
+1.6%
$32.86
+139.8%
-14.8%$621.99M$90.40M-4.31200Analyst Forecast
AUTL
Autolus Therapeutics
2.1426 of 5 stars
$2.28
-1.3%
$9.32
+308.8%
-36.7%$614.79M$10.12M-2.59330
CDXC
ChromaDex
3.2008 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
CDTX
Cidara Therapeutics
4.2057 of 5 stars
$48.71
-1.5%
$57.14
+17.3%
+328.3%$603.74M$1.27M-1.6590Gap Down
High Trading Volume
ABUS
Arbutus Biopharma
1.4563 of 5 stars
$3.09
-1.3%
$5.50
+78.0%
-2.5%$599.48M$6.17M-7.5490
EOLS
Evolus
3.6798 of 5 stars
$9.21
+0.8%
$23.75
+157.9%
-16.6%$589.31M$266.27M-10.35170
UPB
Upstream Bio
1.8336 of 5 stars
$10.98
+0.5%
$56.50
+414.6%
N/A$587.97M$2.37M0.0038News Coverage

Related Companies and Tools


This page (NASDAQ:ACRS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners